ISSN 1662-4009 (online)

ey0019.2-2 | Neonatal hypoglycaemia | ESPEYB19

2.2. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants

T Edwards , G Liu , M Battin , DL Harris , JE Hegarty , PJ Weston , JE Harding

Cochrane Database Syst Rev. 2022 Mar 18;3(3):CD011027. doi: 10.1002/14651858.CD011027.pub3. PMID: 35302645.Brief Summary: This systematic review assessed the evidence for oral dextrose gel to treat hypoglycemia in newborns. Oral dextrose gel compared with placebo gel probably improved the correction of hypoglycaemic events and may result in a slight reduction in the risk of ma...

ey0019.4-6 | Important for clinical practice | ESPEYB19

4.6. Serum testosterone and oestradiol predict the growth response during puberty promoting treatment

H Huttunen , T Varimo , H Huopio , R Voutilainen , S Tenhola , PJ Miettinen , T Raivio , M Hero

Clinical Endocrinology. 2022; 96:220–226. PMID: 34596269Brief Summary: This randomized controlled trial evaluated the effects of testosterone and aromatase inhibitor treatment on anthropometric measures, and their correlation with estradiol and testosterone serum levels in boys with constitutional delay of growth and puberty (CDGP), to elucidate the respective roles of the two sex steroid hormones on growth during puberty. The results sugge...

ey0019.4-7 | Long-acting growth hormone (LAGH) | ESPEYB19

4.7. Effective gh replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3

L Sa¨vendahl , T Battelino , MH Rasmussen , M Brod , P Saenger , R Horikawa

J Clin Endocrinol Metab, 2022. 107(5): p. 1357-1367. PMID: 34964458Brief Summary: This multicenter, randomized, controlled, phase 2 study compared the effects of once-weekly long-acting growth hormone (GH) somapacitan versus daily GH administered to GH-deficient (GHD) children over a period of 156 weeks. Efficacy estimates were height velocity (HV; cm/y) at year 3 and changes from baseline to end for height SDS, HV SDS, IGF-I SDS, and insulin-li...

ey0019.6-6 | Basic and Genetic Research of DSD | ESPEYB19

6.6. Expanding DSD phenotypes associated with variants in the DEAH-box RNA helicase DHX37

H Zidoune , L Martinerie , DS Tan , M Askari , D Rezgoune , A Ladjouze , A Boukri , Y Benelmadani , K Sifi , N Abadi , D Satta , M Rastari , M Seresht-Ahmadi , J Bignon-Topalovic , I Mazen , J Leger , D Simon , R Brauner , M Totonchi , R Jauch , A Bashamboo , K McElreavey

Sex Dev. 2021;15(4):244-252. PMID: 34293745, doi: 10.1159/000515924.Brief Summary: This genetic study provides data of a large cohort of 140 patients with DSD who were screened for DHX37 variants.DHX37 emerges as a frequent cause of nonsyndromic 46,XY gonadal dysgenesis, and 46,XY testicular regression syndrome. Since the first description of the gene (1), <...

ey0019.6-12 | Gender Incongruence: Growth and fertility in transgender girls | ESPEYB19

6.12. Trans girls grow tall: adult height is unaffected by GnRH analogue and estradiol treatment

LS Boogers , CM Wiepjes , DT Klink , I Hellinga , Trotsenburg ASP van , Heijer M den , SE Hannema

J Clin Endocrinol Metab. 2022 Jun 6:dgac349. PMID: 35666195, doi: 10.1210/clinem/dgac349. Brief Summary: This paper reports the adult height of 161 transgender girls (registered male at birth) from the Amsterdam Cohort of Gender Dysphoria. It finds no difference in adult height between use of standard and high estrogen doses. There is currently very little information on...

ey0019.6-15 | Gender Incongruence: Wider impacts of gender affirming hormone (GAH) treatments | ESPEYB19

6.15. Self-perception of transgender adolescents after gender-affirming treatment: a follow-up study into young adulthood

M Arnoldussen , der Miesen AIR van , WS Elzinga , AE Alberse , A Popma , TD Steensma , Vries ALC de

LGBT Health. 2022 May-Jun;9(4):238-246. PMID:35475663, doi: 10.1089/lgbt.2020.0494. Brief Summary: This study reports changes in wellbeing and quality of life in 70 adolescents (49 transgender men and 21 transgender women) from the Amsterdam Center for Expertise on Gender Dysphoria. It finds evidence of improvements in functioning on GAH. The purpose of gender-affirming ...

ey0019.8-6 | Important for Clinical Practice | ESPEYB19

8.6. Characteristics of growth in children with classic Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency during adrenarche and beyond

T Troger , G Sommer , M Lang-Muritano , D Konrad , B Kuhlmann , U Zumsteg , CE Fluck

J Clin Endocrinol Metab. 2022; 107(2): e487-e499. PMID: 34599587https://pubmed.ncbi.nlm.nih.gov/34599587/Brief Summary: This study describes the growth of adequately treated children with classical Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency during adrenarche and beyond. Patients with and without significant bone age advancement, and thus differing height prediction...

ey0019.9-15 | Bone health in chronic disease | ESPEYB19

9.15. Bone health in pediatric patients with Crohn disease

S Rozes , S Guilmin-Crepon , M Alison , E Thomas , JP Hugot , J Viala , C Martinez-Vinson

christine.martinez-vinson@aphp.fr J Pediatr Gastroenterol Nutr. 2021; 73: 231-235. PMID: 33908740.Brief Summary: This retrospective study evaluated longitudinal changes in bone mineral density (BMD) in children and adolescents with Crohn disease (CD), and the risk factors for low BMD. Low BMD (defined as BMD Z score ≤ -2.0) was present in 18.7% of patients at diagnosis and in 16% at ...

ey0019.11-1 | Genetic obesity: findings in clinical cohorts – how to interpret results? | ESPEYB19

11.1. Testing for rare genetic causes of obesity: findings and experiences from a pediatric weight management program

KJ Roberts , AJ Ariza , K Selvaraj , M Quadri , C Mangarelli , S Neault , EE Davis , HJ Binns

robertkj@uwm.edu International Journal of Obesity 2022 May 13:1–9. doi: 10.1038/s41366-022-01139-7. https://pubmed.ncbi.nlm.nih.gov/35562395/Brief Summary: This exploratory study presents the findings and experiences from n=117 children with obesity (BMI &gE;97th percentile for age...

ey0019.11-4 | New findings in adipose tissue biology | ESPEYB19

11.4. Expression of the adipocyte progenitor markers MSCA1 and CD36 is associated with adipose tissue function in children

M Hanschkow , N Boulet , E Kempf , A Bouloumie , W Kiess , R Stein , A Korner , K Landgraf

kathrin.landgraf@medizin.uni-leipzig.de JCEM 2022; 107(2): e836–e851https://pubmed.ncbi.nlm.nih.gov/34448000Brief Summary: This study investigated the association of the novel adipose-derived stem cell (ASC) markers Mesenchymal Stem cell Antigen 1 (MSCA1) and CD36 with adipose tissue function in samples collected from children...